Coeptis Therapeutics Inc Financials
Coeptis Therapeutics Inc (COEP) reported $1.4M in revenue over the twelve months to Mar 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not operating earnings, remains the engine supporting a revenue-generating but loss-making business.
In FY2025, revenue of$1.36M yielded$1.18M of gross profit, yet operating cash flow was-$8.60M . Because financing cash flow supplied$13.74M , commercial activity exists but is not yet the source of cash supporting the cost base.
Gross margin was
From FY2021 to FY2025, total liabilities fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Coeptis Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Coeptis Therapeutics Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.
Not available for Coeptis Therapeutics Inc, and counted as zero in the overall score.
Coeptis Therapeutics Inc carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.16, Coeptis Therapeutics Inc holds $4.16 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.
Not available for Coeptis Therapeutics Inc, and counted as zero in the overall score.
Coeptis Therapeutics Inc posts a -87.9% return on equity (ROE), meaning it loses $88 for every $100 of shareholders' equity. This results in a returns score of 5/100. This is up from -315.8% the prior year.
Coeptis Therapeutics Inc scores 17.66, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($102.1M) relative to total liabilities ($2.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Coeptis Therapeutics Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Coeptis Therapeutics Inc reported a net loss of $11.9M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Coeptis Therapeutics Inc reported an operating loss of $13.0M against $97K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Coeptis Therapeutics Inc generated $1.4M in revenue in fiscal year 2025.
Coeptis Therapeutics Inc's EBITDA was -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.0% from the prior year.
Coeptis Therapeutics Inc reported -$11.9M in net income in fiscal year 2025. This represents a decrease of 11.6% from the prior year.
Coeptis Therapeutics Inc earned -$2.81 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Coeptis Therapeutics Inc held $5.7M in cash against $150K in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Coeptis Therapeutics Inc's gross margin was 86.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Coeptis Therapeutics Inc's ROE was -87.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 227.9 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Coeptis Therapeutics Inc invested $1.3M in research and development in fiscal year 2025. This represents a decrease of 45.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
COEP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114K-86.8% | $862K+263.1% | $237K+18.3% | $201K+219.2% | $63K | N/A | $0 | $0 |
| Cost of Revenue | $45K0.0% | $45K0.0% | $45K0.0% | $45K0.0% | $45K | N/A | $0 | $0 |
| Gross Profit | $69K-91.6% | $817K+324.8% | $192K+23.6% | $156K+777.8% | $18K | N/A | $0 | $0 |
| R&D Expenses | $236K-24.7% | $313K-46.7% | $587K+102.3% | $290K+235.0% | $87K | N/A | $812K+103.5% | $399K |
| SG&A Expenses | N/A | N/A | $201K-61.8% | $527K+95.9% | $269K | N/A | $173K-27.6% | $239K |
| Operating Income | -$3.9M-96.9% | -$2.0M+19.7% | -$2.5M+45.2% | -$4.5M-11.4% | -$4.1M | N/A | -$2.1M+24.3% | -$2.8M |
| Interest Expense | $5K+105.0% | -$105K-267.9% | $63K-7.6% | $68K-5.2% | $71K | N/A | $51K-22.9% | $66K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$4.0M-218.4% | -$1.3M+56.4% | -$2.9M+33.1% | -$4.3M-26.7% | -$3.4M | N/A | -$1.8M+39.7% | -$3.0M |
| EPS (Diluted) | -$0.65 | N/A | -$0.58 | -$1.17-6.4% | -$1.10 | N/A | -$0.05+37.5% | -$0.08 |
COEP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.8M+22.5% | $16.2M+13.9% | $14.2M+16.3% | $12.2M-9.4% | $13.5M+51.0% | $8.9M-0.5% | $9.0M+113.3% | $4.2M |
| Current Assets | $5.9M-19.6% | $7.4M+22.7% | $6.0M+62.1% | $3.7M-20.6% | $4.7M+342.4% | $1.1M-23.0% | $1.4M-31.5% | $2.0M |
| Cash & Equivalents | $5.2M-8.2% | $5.7M+15.6% | $4.9M+145.8% | $2.0M-53.2% | $4.3M+701.0% | $533K-53.2% | $1.1M-26.9% | $1.6M |
| Accounts Receivable | N/A | N/A | $83K+175.0% | $30K | N/A | $0 | N/A | N/A |
| Total Liabilities | $2.2M+5.9% | $2.1M-36.1% | $3.3M-36.1% | $5.1M-14.7% | $6.0M+18.8% | $5.0M+26.9% | $4.0M-11.9% | $4.5M |
| Current Liabilities | $1.8M+2.8% | $1.8M-34.6% | $2.7M-39.5% | $4.5M-20.8% | $5.7M+25.2% | $4.5M+31.2% | $3.4M-5.1% | $3.6M |
| Long-Term Debt | $150K0.0% | $150K0.0% | $150K0.0% | $150K | N/A | $150K0.0% | $150K0.0% | $150K |
| Total Equity | $17.2M+26.7% | $13.6M+30.8% | $10.4M+70.0% | $6.1M-5.9% | $6.5M+91.6% | $3.4M-29.9% | $4.8M+1190.2% | -$443K |
| Retained Earnings | -$113.9M-3.6% | -$110.0M-1.5% | -$108.4M-2.3% | -$106.0M-4.3% | -$101.7M-3.7% | -$98.0M-3.0% | -$95.2M-2.0% | -$93.4M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
COEP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.8M-4.2% | -$1.7M+21.6% | -$2.2M+10.2% | -$2.4M-1.3% | -$2.4M-64.7% | -$1.4M+24.1% | -$1.9M-33.5% | -$1.4M |
| Investing Cash Flow | $592K | $0 | $0 | $0 | $0-100.0% | $100K | $0 | $0 |
| Financing Cash Flow | $704K-71.3% | $2.5M-51.5% | $5.1M+3947.9% | $125K-97.9% | $6.1M+733.6% | $732K-50.4% | $1.5M-24.1% | $1.9M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
COEP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3%-34.5pp | 94.8%+13.8pp | 81.0%+3.5pp | 77.5%+49.3pp | 28.2% | N/A | N/A | N/A |
| Operating Margin | -3440.8% | -230.6% | -1043.2% | -2252.9% | -6452.6% | N/A | N/A | N/A |
| Net Margin | -3534.2% | -146.5% | -1220.8% | -2159.9% | -5440.9% | N/A | N/A | N/A |
| Return on Equity | -23.4%-14.1pp | -9.3%+18.7pp | -28.0%+43.1pp | -71.1%-18.3pp | -52.8% | N/A | -37.9% | N/A |
| Return on Assets | -20.3%-12.5pp | -7.8%+12.6pp | -20.4%+15.1pp | -35.5%-10.1pp | -25.4% | N/A | -20.4%+51.9pp | -72.3% |
| Current Ratio | 3.25-0.9x | 4.16+1.9x | 2.21+1.4x | 0.830.0x | 0.82+0.6x | 0.23-0.2x | 0.40-0.2x | 0.55 |
| Debt-to-Equity | 0.010.0x | 0.010.0x | 0.010.0x | 0.02-0.9x | 0.92+0.9x | 0.040.0x | 0.03 | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Coeptis Therapeutics Inc Ranks
Frequently Asked Questions
What is Coeptis Therapeutics Inc's annual revenue?
Coeptis Therapeutics Inc (COEP) reported $1.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Coeptis Therapeutics Inc profitable?
No, Coeptis Therapeutics Inc (COEP) reported a net income of -$11.9M in fiscal year 2025.
What is Coeptis Therapeutics Inc's EBITDA?
Coeptis Therapeutics Inc (COEP) had EBITDA of -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Coeptis Therapeutics Inc have?
As of fiscal year 2025, Coeptis Therapeutics Inc (COEP) had $5.7M in cash and equivalents against $150K in long-term debt.
What is Coeptis Therapeutics Inc's gross margin?
Coeptis Therapeutics Inc (COEP) had a gross margin of 86.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Coeptis Therapeutics Inc's return on equity (ROE)?
Coeptis Therapeutics Inc (COEP) has a return on equity of -87.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Coeptis Therapeutics Inc's operating cash flow?
Coeptis Therapeutics Inc (COEP) recorded an outflow of $8.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Coeptis Therapeutics Inc's total assets?
Coeptis Therapeutics Inc (COEP) had $16.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Coeptis Therapeutics Inc spend on research and development?
Coeptis Therapeutics Inc (COEP) invested $1.3M in research and development during fiscal year 2025.
What is Coeptis Therapeutics Inc's current ratio?
Coeptis Therapeutics Inc (COEP) had a current ratio of 4.16 as of fiscal year 2025, which is generally considered healthy.
What is Coeptis Therapeutics Inc's debt-to-equity ratio?
Coeptis Therapeutics Inc (COEP) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Coeptis Therapeutics Inc's return on assets (ROA)?
Coeptis Therapeutics Inc (COEP) had a return on assets of -73.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Coeptis Therapeutics Inc's Altman Z-Score?
Coeptis Therapeutics Inc (COEP) has an Altman Z-Score of 17.66, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Coeptis Therapeutics Inc's Piotroski F-Score?
Coeptis Therapeutics Inc (COEP) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Coeptis Therapeutics Inc's earnings high quality?
Coeptis Therapeutics Inc (COEP) reported a net loss of $11.9M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Coeptis Therapeutics Inc cover its interest payments?
Coeptis Therapeutics Inc (COEP) reported an operating loss of $13.0M against $97K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Coeptis Therapeutics Inc?
Coeptis Therapeutics Inc (COEP) scores 30 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.